| Asthma
Advair Diskus vs Qvar RediHaler
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Advair vs Qvar Redihaler with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQvar Redihaler has a higher rate of injection site reactions vs Advair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qvar Redihaler but not Advair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair
Qvar Redihaler
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Twice daily
Inhaled corticosteroid
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma 1 inhalation twice daily approximately 12 hours apart; adults and adolescents aged >=12 years may use 100/50, 250/50, or 500/50 strengths (max ADVAIR DISKUS 500/50 twice daily); pediatric patients aged 4 to 11 years use 1 inhalation of ADVAIR DISKUS 100/50 twice daily.
Chronic Obstructive Airway Disease 1 inhalation of ADVAIR DISKUS 250/50 twice daily approximately 12 hours apart.
Asthma (adults and adolescents, >=12 years) 40 to 320 mcg twice daily by oral inhalation, approximately 12 hours apart; starting dose 40 to 80 mcg twice daily for those not on an inhaled corticosteroid; maximum 320 mcg twice daily.
Asthma (pediatric, 4 to 11 years) 40 mcg twice daily by oral inhalation, approximately 12 hours apart; may increase to 80 mcg twice daily after 2 weeks if needed; maximum 80 mcg twice daily.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients
- Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures
- Known hypersensitivity to beclomethasone dipropionate or any ingredient in QVAR REDIHALER
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, pharyngitis, headaches, candidiasis mouth/throat, throat irritation, hoarseness/dysphonia, musculoskeletal pain, viral respiratory infections, nausea and vomiting, bronchitis, sinusitis, dizziness, muscle cramps and spasms
Serious Serious asthma-related events (hospitalizations, intubations, death), pneumonia in patients with COPD, cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma and cataracts
Postmarketing Arrhythmias (including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia), Cushing's syndrome, glaucoma, hyperglycemia, osteoporosis, paradoxical bronchospasm, immediate and delayed hypersensitivity reactions including anaphylaxis, agitation, depression, dysmenorrhea
Most common (>=3%) oral candidiasis, upper respiratory tract infection, nasopharyngitis, oropharyngeal pain, viral upper respiratory tract infection, sinusitis, pharyngitis, headache, pyrexia
Serious oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing localized Candida infections, aggression, depression, sleep disorders, psychomotor hyperactivity, suicidal ideation (primarily in children), blurred vision, central serous chorioretinopathy
Pharmacology
ADVAIR DISKUS combines fluticasone propionate, a synthetic trifluorinated corticosteroid that suppresses airway inflammation by acting on multiple cell types and mediators, and salmeterol, a selective long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Inhaled corticosteroid prodrug; beclomethasone dipropionate is rapidly hydrolyzed to the active monoester 17-monopropionate (17-BMP), which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) to reduce airway inflammation in asthma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Qvar Redihaler
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Advair
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Qvar Redihaler
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Advair
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (3/3)
Qvar Redihaler
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair.
No savings programs available for Qvar Redihaler.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdvairView full Advair profile
Qvar RedihalerView full Qvar Redihaler profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.